Final development and validation of the BOMET-QoL questionnaire for assessing quality of life in patients with malignant bone disease due to neoplasia

Impact of skeletal complications on patients’ quality of life, mobility, and functional independence

“…Scores from the BOMET-QoL assessment had good reliability as measured by internal consistency and test-retest criteria [66]. The final validated version, the BOMET-QoL-10, consists of 10 questions scored on a 5-point scale (Table 1) [2,66]. For patients with bone metastases, BOMET-QoL-10 questions are intended to determine whether the patient experiences pain typical of the disease (intense, constant) and whether pain is localized to common metastatic sites [2,66].…”

“…Furthermore, BOMET-QoL scores appear to be sensitive to changes in HRQOL status and ECOG performance status, but appear to be more sensitive to changes in the midline (Fig. 6) [66]. Scores from the BOMET-QoL assessment had good reliability as measured by internal consistency and test-retest criteria [66].…”

“…Reprinted by permission from Macmillan Publishers Ltd from [75], copyright 2005 metastases are now being developed. The BOMET-QoL is the first bone metastases-specific assessment of HRQOL, and the validation study in patients with bone lesions from lung cancer, prostate cancer, breast cancer, or multiple myeloma has shown that statistically significant differences are not observed between key demographic groups (e.g., age, sex, and education) [66]. The BOMET-QoL scores correlated with the presence and duration of pain crises, with the Pain Management Index, and-to a certain extent-with Eastern Cooperative Oncology Group (ECOG) performance status.…”

“…6) [66]. Scores from the BOMET-QoL assessment had good reliability as measured by internal consistency and test-retest criteria [66]. The final validated version, the BOMET-QoL-10, consists of 10 questions scored on a 5-point scale (Table 1) [2,66].…”

“…Although a number of methods to assess HRQOL are available (e.g., Spitzer QL-Index [64] [23], and the EQ-5D [31]), these instruments do not directly assess the unique combination of bone complications and pain that affects patients with malignant bone disease. To address this issue, the Bone Metastases Quality-of-Life questionnaire (BOMET-QoL) and the BM-22 module to the EORTC QLQ-C30 have recently been designed [2,34,66]. The BOMET-QoL was intended to be a simple, self-administered questionnaire for use in clinical research and to monitor patient HRQOL status including mobility and functional impairment.…”